HMMR and neoplasm: Beyond genetic and epigenetic control, various novel RHAMM-targeting strategies, including function-blocking peptides, HA oligomers, and anti-RHAMM antibodies, offer promising opportunities to disrupt tumor stroma, reduce invasiveness, and potentially enhance immune responses.